In particular, the V617F JAK2 mutation, which is found in most patients with polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis, makes this kinase a potential therapeutic target to treat patients suffering from these types of cancer [35,36,37,38,39]. Here, JAK2 is linked to primary myelofibrosis.